File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Current antiviral therapy of chronic hepatitis B: Efficacy and safety

TitleCurrent antiviral therapy of chronic hepatitis B: Efficacy and safety
Authors
Lam, YFYuen, MFSeto, WKLai, CL
KeywordsHBV DNA
Hepatitis B
Nucleos(t)ide Analogs
Resistance
Issue Date2011
PublisherSpringer Healthcare. The Journal's web site is located at http://www.springerlink.com/content/1540-3416/
Citation
Current Hepatitis Reports, 2011, v. 10 n. 4, p. 235-243 How to Cite?
DOI: http://dx.doi.org/10.1007/s11901-011-0109-z
AbstractThe treatment of chronic hepatitis B is in constant evolution. Interferon, the first agent licensed for chronic hepatitis B treatment, has been superseded by the growing popularity of nucleoside/nucleotide analogues (NA). However, resistance to these agents is a major challenge. Newer NAs, such as entecavir and tenofovir dipivoxil fumarate, have very low resistance rates and favorable safety profiles. Long-term use of these agents can effectively suppress hepatitis B virus DNA, leading to decrease in incidence of hepatitic flares, as well as in the development of cirrhosis and hepatocellular carcinoma. The efficacy and safety of various antiviral agents is discussed in this review. © 2011 The Author(s).
Persistent Identifierhttp://hdl.handle.net/10722/144892
ISSN
1540-3416
PubMed Central ID
PMC3210946
References
References in Scopus

 

DC FieldValueLanguage
dc.contributor.authorLam, YFen_HK
dc.contributor.authorYuen, MFen_HK
dc.contributor.authorSeto, WKen_HK
dc.contributor.authorLai, CLen_HK
dc.date.accessioned2012-02-21T05:44:09Z-
dc.date.available2012-02-21T05:44:09Z-
dc.date.issued2011en_HK
dc.identifier.citationCurrent Hepatitis Reports, 2011, v. 10 n. 4, p. 235-243en_HK
dc.identifier.issn1540-3416en_HK
dc.identifier.urihttp://hdl.handle.net/10722/144892-
dc.description.abstractThe treatment of chronic hepatitis B is in constant evolution. Interferon, the first agent licensed for chronic hepatitis B treatment, has been superseded by the growing popularity of nucleoside/nucleotide analogues (NA). However, resistance to these agents is a major challenge. Newer NAs, such as entecavir and tenofovir dipivoxil fumarate, have very low resistance rates and favorable safety profiles. Long-term use of these agents can effectively suppress hepatitis B virus DNA, leading to decrease in incidence of hepatitic flares, as well as in the development of cirrhosis and hepatocellular carcinoma. The efficacy and safety of various antiviral agents is discussed in this review. © 2011 The Author(s).en_HK
dc.languageengen_US
dc.publisherSpringer Healthcare. The Journal's web site is located at http://www.springerlink.com/content/1540-3416/en_HK
dc.relation.ispartofCurrent Hepatitis Reportsen_HK
dc.rights© The Author(s) 2011.en_US
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.en_US
dc.subjectHBV DNAen_HK
dc.subjectHepatitis Ben_HK
dc.subjectNucleos(t)ide Analogsen_HK
dc.subjectResistanceen_HK
dc.titleCurrent antiviral therapy of chronic hepatitis B: Efficacy and safetyen_HK
dc.typeArticleen_HK
dc.identifier.emailYuen, MF: mfyuen@hku.hken_HK
dc.identifier.emailSeto, WK: wkseto2@hku.hken_HK
dc.identifier.emailLai, CL: hrmelcl@hku.hken_HK
dc.identifier.authorityYuen, MF=rp00479en_HK
dc.identifier.authoritySeto, WK=rp01659en_HK
dc.identifier.authorityLai, CL=rp00314en_HK
dc.description.naturepublished_or_final_versionen_US
dc.identifier.doi10.1007/s11901-011-0109-zen_HK
dc.identifier.pmid22131901-
dc.identifier.pmcidPMC3210946-
dc.identifier.scopuseid_2-s2.0-81355147539en_HK
dc.identifier.hkuros210690-
dc.identifier.hkuros208899-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-81355147539&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume10en_HK
dc.identifier.issue4en_HK
dc.identifier.spage235en_HK
dc.identifier.epage243en_HK
dc.identifier.eissn1541-0706en_US
dc.publisher.placeUnited Statesen_HK
dc.description.otherSpringer Open Choice, 21 Feb 2012en_US
dc.identifier.scopusauthoridLam, YF=45661458000en_HK
dc.identifier.scopusauthoridYuen, MF=7102031955en_HK
dc.identifier.scopusauthoridSeto, WK=23390675900en_HK
dc.identifier.scopusauthoridLai, CL=7403086396en_HK
dc.identifier.citeulike9686292-
dc.identifier.issnl1540-3416-

Export via OAI-PMH Interface in XML Formats

OR

Export to Other Non-XML Formats